Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Hubei Aoxiang Fine Chemical was a Wuhan, China-based fine chemical trading and development company rather than a drug developer or healthcare operating company. Publicly accessible company-registration data describes its business scope as fine chemical development and sales, plus technical services and promotion related to biomedicine, cosmetics, food additives, biotechnology, and health products. Third-party supplier listings suggest it marketed chemical ingredients and related products, but there is no clear evidence of a therapeutic pipeline, clinical programs, or proprietary healthcare products. Available records indicate the company was founded in 2011 and later deregistered in 2021. Based on the currently available evidence, it should not be classified as a biotech/pharma company in the usual analyst sense.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Hubei Aoxiang Fine Chemical.